Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Income towards Parent Company (2024 - 2025)

Historic Income towards Parent Company for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $1.8 million.

  • Neuphoria Therapeutics' Income towards Parent Company rose 19345.74% to $1.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$12.0 million, marking a year-over-year decrease of 34063.73%. This contributed to the annual value of -$6.6 million for FY2025, which is 5711.94% up from last year.
  • Neuphoria Therapeutics' Income towards Parent Company amounted to $1.8 million in Q4 2025, which was up 19345.74% from -$9.9 million recorded in Q3 2025.
  • Over the past 5 years, Neuphoria Therapeutics' Income towards Parent Company peaked at $11.3 million during Q1 2025, and registered a low of -$15.2 million during Q2 2025.